Published in J Med Chem on July 15, 2004
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Antiandrogenic properties of parabens and other phenolic containing small molecules in personal care products. Toxicol Appl Pharmacol (2007) 1.13
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des (2011) 0.97
In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology (2005) 0.97
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res (2006) 0.97
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem (2007) 0.96
Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv (2005) 0.95
Synthesis of irreversibly binding bicalutamide analogs for imaging studies. Tetrahedron Lett (2005) 0.85
Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators. Bioorg Med Chem Lett (2008) 0.85
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem (2010) 0.82
Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer. Bioorg Med Chem (2006) 0.79
Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer. J Pharmacol Exp Ther (2006) 0.77
Synthesis of oxazolidinedione derived bicalutamide analogs. Tetrahedron Lett (2006) 0.75
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome. Hum Mol Genet (1992) 1.40
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J Med Chem (2001) 1.33
Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol (1999) 1.23
Specific recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem (2000) 1.16
Three-dimensional quantitative structure--activity relationships for androgen receptor ligands. Toxicol Appl Pharmacol (1996) 1.09
Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg Med Chem Lett (1999) 1.08
DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J Med Chem (2002) 1.01
Replacement of steric 6-12 potential-derived interaction energies by atom-based indicator variables in CoMFA leads to models of higher consistency. J Comput Aided Mol Des (1995) 0.91
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
Status of PharmD/PhD programs in colleges of pharmacy: the University of Tennessee dual PharmD/PhD program. Am J Pharm Educ (2006) 2.35
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol (2013) 1.78
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem (2003) 1.61
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett (2004) 1.57
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm Res (2006) 1.51
Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy. Am J Obstet Gynecol (2006) 1.50
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci (2012) 1.46
The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology (2007) 1.42
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
An expiratory assist during spontaneous breathing can compensate for endotracheal tube resistance. Anesth Analg (2009) 1.41
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Camptothecins: a review of their chemotherapeutic potential. Drugs (2002) 1.40
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem (2008) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem (2007) 1.36
Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res (2003) 1.34
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med (2013) 1.33
Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry (2004) 1.33
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem (2009) 1.27
Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm Res (2007) 1.25
A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther (2004) 1.25
Structure-function analysis of barley NLR immune receptor MLA10 reveals its cell compartment specific activity in cell death and disease resistance. PLoS Pathog (2012) 1.25
Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 1.25
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst (2003) 1.25
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids (2008) 1.24
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem (2007) 1.22
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res (2010) 1.21
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm (2008) 1.21
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett (2005) 1.19
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta (2007) 1.18
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Continuous production of lipase-catalyzed biodiesel in a packed-bed reactor: optimization and enzyme reuse study. J Biomed Biotechnol (2010) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc Natl Acad Sci U S A (2005) 1.15
Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev (2003) 1.13
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
A comprehensive approach to faculty development. Am J Pharm Educ (2006) 1.11
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem (2011) 1.09
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci (2008) 1.09
Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res (2009) 1.07
VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov (2012) 1.06
Fluorescent nanoparticle-based indirect immunofluorescence microscopy for detection of Mycobacterium tuberculosis. J Biomed Biotechnol (2007) 1.05
Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm Res (2010) 1.04
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther (2005) 1.04